Fritextsökning
Artiklar per år
-
Biovitrum och Karolinska bildar bolag
Forskningen kring ett av läkemedelsföretagets projekt ska nu drivas vidare i gemensam regi.
-
Aktiv kräm gav färre finnar
Färre utbrott av acne och färre inflammationer blev resultatet av tolv veckors idogt smörjande. Det visar en nyss avslutad dansk studie.
-
Mot börsen med kassan full
Det norska cancerforskningsföretaget Algeta tar in 35 miljoner US-dollar för att fortsätta utvecklingen av sitt mest lovande cancerprojekt.
-
Det som inte syns, finns inte - eller?
Fler män än kvinnor får forsknings- stöd, och av de stöd som delas ut går de största summorna till män. Är det någon som är förvånad?
-
Euris avnoteras
Styrelsen har beslutat att lista om bolaget på en annan handelsplats, för att minska kraven på administration.
-
Stamceller kan stoppa svår MS
Forskare vid Uppsala universitet visar att det är möjligt att stoppa sjukdomen multipel skleros. Genom att behandla patienter med blodstamceller har man lyckats stoppa sjukdomsförloppet.
-
Finns det grodor så finns det hopp
Forskare har identifierat ett ämne som blockerar det pigment som gör grodyngel fläckiga. På sikt kan rönen leda till bättre behandling av hudcancer.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
A smart company takes care of its best
Lundbeck didn't have to look far to find it's new international Director of Marketing. The talent was already in the house.
-
New CEO to Promedvi
Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.
-
Almost 150 will leave Coloplast
The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Hormones make children fat
A new Danish million project will define the connection between hormons and obesity amongst children.
-
Medicult needs a word of advice
Medicult Board retains advisers, regarding the previous offer from Vitrolife.
-
Biovitrum sells UK part
Biovitrum will soon spin-out a British subsidary
-
Biotech goes white and bright
White biotech could become Denmark's next blossoming business area.
-
Eli Lilly writes biotech fine history
The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.
-
Abbott expands by acquisition
An acquisition gives Abbott a leadership position in another large and growing medical device segment.
-
Dupont gets new business manager
The Swedish API manufacturer Dupont Chemoswed has appointed a new business development manager.
-
Swedish multi competent machine soon launched
The Swedish company Biosensor will launch new equipment able to detect twelve different narcotics and explosives simultaneously.
BREAKING